Alumis Inc. (NASDAQ: ALMS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 [Yahoo! Finance]
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
Alumis Inc. (NASDAQ: ALMS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.